AstraZeneca Boosts Rare Disease Pipeline With Ionis Antisense Candidate

AstraZeneca has bulked up its late-stage pipeline with an agreement for Ionis’s eplontersen which is in trials for two rare diseases, quelling some analysts’ fears about the scarcity of catalysts for next year.